Vitae Pharmaceuticals' Unique Discovery Engine
CONTOUR® structure-based drug design – a product discovery engine for a sustainable pipeline
Vitae Pharmaceuticals, Inc. was founded with the goal of accelerating and improving innovation in small molecule drug discovery, specifically by creating and operationalizing a paradigm breakthrough in structure-based drug design technology that can be coupled with scientific expertise to create novel compounds. This unique and proprietary discovery engine – called CONTOUR® – leverages and enhances the abilities of Vitae Pharmaceuticals' world class team of scientists to discover and develop targeted small molecule compounds in a broad range of therapeutic areas to serve patients in need. By harnessing the power of CONTOUR® structure based drug design (SBDD), Vitae Pharmaceuticals' accomplished team can optimize the properties of the compounds they discover and shorten the time required to advance these compounds into the clinic.
The CONTOUR® technology platform is comprised of a robust, combinatorially efficient growth algorithm (growth engine), a high-performance computational infrastructure, and structural biology integrated with traditional medicinal chemistry and biology functions for innovative structure-based design. It is guided by a team of highly trained scientists to design the best possible compounds and move them through the development process.
Vitae Pharmaceuticals’ successful programs on three very difficult targets: renin, 11ß-HSD-1 and beta secretase, have proven the advantages of CONTOUR® SBDD. The platform has consistently generated novel, patentable leads within 2-7 months and animal proof-of-concept data within 14-16 months after the start of a program.